Clinical trial · Interventional
Efficacy of Atomoxetine Therapy Versus Placebo for Cognitive Late Effects
Efficacy of Atomoxetine Therapy Versus Placebo For Ameliorating Cognitive Late Effects Among Survivors of Childhood Cancers
NCT00255138CI-TRIAL-00057489withdrawnPhase 3ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of the study is to evaluate the effectiveness and safety of atomoxetine in enhancing attention and concentration among childhood survivors of cancer.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cancer | Malignant Neoplasm | ALIAS | 0.90 |
| Cognitive Late Effects | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Atomoxetine | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Conner's Parent Rating Scale (CPRS)
Secondary outcomes (3)
- measure
- Conner's Teacher Rating Scale (CTRS)
- measure
- Continuous Performance Test (CPT)
- measure
- Side Effects Rating Scale
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 6 Years
- Maximum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Age 6-18 * Patient has received chemotherapy, radiation, or a combination of both. * Patient is at least 12 months post-competion of therapy but no more than five years post-completion of therapy. Exclusion Criteria: * No ongoing pharmacological management of ADHD * Not currently pregnant
References
Publications (0)
Data not yet available
No reference posted for this study.